Yongxin Ren

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Shun Lü, Jian Fang, Xingya Li et al. · The Lancet Respiratory Medicine · 2021 · 204 citations

Medicine, Oncology, Pharmacology +11

FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging

Hanjun Li, Pei Liu, Shuqin Xu et al. · Journal of Clinical Investigation · 2017 · 184 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Qiaoling Sun, Jinghong Zhou, Zheng Zhang et al. · Cancer Biology & Therapy · 2014 · 153 citations · Full text

Medicine, Oncology, Pharmacology +13

Discovery of (<i>S</i>)-1-(1-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 134 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models

Paul R. Gavine, Yongxin Ren, Lu Han et al. · Molecular Oncology · 2014 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17